Cancer Treatment Reviews
Volume 29, Issue 3 , Page 223, June 2003

Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer:☆☆☆★

Abstracted from: Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95:361–376.

Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennoudai, Tsukuba City, Ibaraki, Japan

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Agency for Healthcare Research and Quality.

☆☆ For correspondence to: DJ Samson, Blue Cross and Blue Shield Association, Washington DC 20005, USA. E-mail: david.samson@wro.bcbsa.com

★ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(03)00098-7

doi:10.1016/S0305-7372(03)00098-7

Cancer Treatment Reviews
Volume 29, Issue 3 , Page 223, June 2003

Article Tools